Veeva Systems Inc. research snapshot
VEEV AI stock analysis currently reads Veeva Systems as a high-quality life sciences software company with durable customer switching costs, a large cash balance, and a new AI product cycle across Vault AI, Falcon, Agentic Commercial, and Ostro. Veeva reported fiscal Q1 2027 revenue of $882.9 million, up 16%, net income of $260.9 million, non-GAAP diluted EPS of $2.24, and cash plus short-term investments of about $7.31 billion. The caution is that VEEV still depends on large regulated software budgets, successful Vault CRM migration, and continued AI monetization. At the July 8, 2026 intraday reference of $189.02 and 162.44 million shares outstanding, the verified market cap was about $30.71 billion. This VEEV AI stock forecast is scenario-based, not a precise price prediction, and should be used as an informational research tool, not investment advice.
Current price
$189.02 intraday reference on July 8, 2026
Market cap
$30.71 billion equity value
AI score
76 / 100
Rating
High-quality vertical software platform with strong cash generation, founder-led execution, and valuation sensitivity after a 2026 reset
Trend status
Above 50-day and 200-day moving averages, but below the 5-day, 10-day, and 20-day averages after a short pullback
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Veeva sells industry cloud software, data, AI, and consulting to life sciences companies across commercial, medical, clinical, regulatory, quality, and safety workflows. | High |
| Moat | The moat comes from regulated workflow depth, industry-specific product breadth, customer switching costs, validated data processes, domain trust, and a large installed base across pharma and biotech. | Medium-high |
| Management | Founder and CEO Peter Gassner still directs strategy, product direction, and operations, while investors must watch capital allocation, buybacks, acquisitions, and execution after the Salesforce platform separation. | Medium-high |
| Financial trend | Q1 fiscal 2027 revenue rose 16% to $882.9 million, subscription revenue rose 15% to $730.2 million, net income rose 14% to $260.9 million, and operating cash flow reached $1.13 billion. | High |
| Valuation | At $189.02, VEEV screened near 33.5x trailing EPS, 20.9x fiscal 2027 non-GAAP EPS guidance, 4.2x book value, 18.7x free cash flow per share, and 9.3x sales per share in the audited model. | High |
| Technical trend | The stock is above the 50-day and 200-day moving averages, but the July 8 pullback left it below shorter 5-day, 10-day, and 20-day references, making the setup constructive but not cleanly extended. | Medium |
| Risk level | Key risks are Salesforce and IQVIA competition, Vault CRM migration risk, clinical trial and pharma budget cycles, drug pricing and regulatory pressure, AI monetization uncertainty, customer concentration in life sciences, and valuation compression. | Medium-high |
| AI confidence | Descriptive data confidence is high because Veeva provides current official releases and third-party market data is available for cross-checks. | High data confidence |
| Investment certainty | VEEV looks like a high-quality vertical software compounder at a more reasonable 2026 multiple, but not a low-risk bargain because the stock still prices in successful AI and Vault CRM execution. | Medium |
VEEV AI stock forecast
The VEEV AI stock forecast uses the July 8, 2026 intraday reference of $189.02, fiscal 2027 non-GAAP EPS guidance of about $9.05, and a three-year earnings multiple framework. The financial_rigor.py model produced a bearish area near $178, a base area near $289, and a bullish area near $413 before buybacks, dilution, acquisition effects, interest income changes, or further multiple changes. These are scenario ranges, not promises.
$390 to $420
More likely if Veeva keeps revenue growth in the mid-teens, Vault CRM migration strengthens account control, AI products become paid workflow layers, non-GAAP operating margin stays near the mid-40% area, and investors keep paying around 30x forward earnings.
$275 to $300
More likely if EPS grows around 10% annually, fiscal 2027 revenue lands near the $3.64 billion guidance midpoint, subscription growth stays durable, buybacks offset dilution, and VEEV trades near a 24x earnings multiple.
$170 to $185
More likely if Salesforce Life Sciences Cloud or IQVIA pressure CRM wins, AI features fail to lift spending, clinical trial budgets weaken, margin expansion slows, or software multiples compress toward 18x earnings.
VEEV AI technical analysis
VEEV AI technical analysis is mixed to constructive as of the July 8, 2026 data cutoff. StockAnalysis listed an intraday price of $189.02, while Investing.com showed RSI near 50, MACD positive, 50-day simple moving average near $184.17, and 200-day simple moving average near $170.75. The short-term pullback matters because the same Investing.com snapshot placed the 5-day, 10-day, and 20-day moving averages above price.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $189.02 | July 8, 2026 intraday reference used for market cap and valuation math. |
| Immediate support | $184 to $188 | The 50-day moving average and classic pivot support levels cluster in this zone. |
| Secondary support | $170 to $172 | The 100-day and 200-day moving-average area is the larger trend support zone. |
| Breakdown support | $153 to $155 | AltIndex identified six-month support near $153.16, close to the broader post-reset support area. |
| Near resistance | $190 to $194 | Classic pivot resistance and the 5-day, 10-day, and 20-day moving-average cluster sit near this area. |
| Major resistance | $212 to $225 | Barchart listed the 200-day average near $212.10, while AltIndex placed six-month resistance near $225.28. |
| Moving averages | 20-day near $192, 50-day near $184, 200-day near $171 | Price above the 50-day and 200-day supports trend repair, while price below the 20-day shows a near-term pause. |
| Momentum | RSI near 50 with positive MACD | Momentum is balanced rather than overbought in the Investing.com July 8 snapshot. |
| Volume | 20-day average near 2.6 million shares | Breakouts above $194 and $225 should be judged against above-average volume. |
| Volatility | ATR near $2.08 on Investing.com and near $7.33 on Barchart | Different vendors use different ATR windows and price feeds, so risk controls should allow for wide SaaS stock movement around earnings. |
| Invalidation | Close below $184, then below $170 | A close below the 50-day area weakens the rebound, while a break below the 200-day zone would damage the larger trend repair setup. |
VEEV AI trading strategy
The VEEV AI trading strategy below is a rules-based research framework, not personal advice. It connects technical levels with Veeva AI adoption, Vault CRM migration, subscription revenue, operating margin, cash generation, buybacks, and competitive displacement signals.
Watch for VEEV to hold $184 to $188 support and reclaim $190 to $194 on stronger volume while the next earnings update confirms mid-teens revenue growth, durable subscription demand, and raised or maintained fiscal 2027 guidance.
A failed move above the short-term moving averages followed by a close below $184 should reduce setup confidence, especially if management commentary points to slower Vault CRM migration or weaker commercial solution demand.
If VEEV pulls back toward the $170 to $184 zone without a cut to revenue, EPS, or cash-flow guidance, compare the new price with the verified 33.5x trailing EPS, 20.9x fiscal 2027 non-GAAP EPS guidance, and 18.7x free cash flow references.
Do not treat a lower price as enough if Salesforce or IQVIA wins major accounts, AI pricing fails to convert, or pharma and biotech budgets weaken.
Track total revenue, subscription revenue, Commercial Solutions and R&D and Quality Solutions growth, Vault CRM customer migration, AI product rollout, customer count, non-GAAP operating margin, operating cash flow, share count, and cash plus short-term investments.
Position sizing should reflect that Veeva is a strong vertical software platform, but still exposed to software multiple resets and sector-specific life sciences spending cycles.
Investment research summary
Customers pay Veeva to run regulated life sciences workflows with cloud software, data, AI, and services across drug development, quality, safety, medical, commercial, and customer engagement processes.
The moat comes from industry-specific product depth, validated regulatory workflows, customer switching costs, domain trust, data models, implementation knowledge, and a customer base that includes large biopharma and emerging biotech companies.
The thesis fails if Vault CRM migration disappoints, Salesforce Life Sciences Cloud wins key accounts, AI becomes a cost of doing business rather than paid expansion, drug development budgets weaken, or the market stops paying premium multiples for vertical SaaS.
Peter Gassner founded Veeva in 2007 and remains CEO. Founder leadership is a strength, but it also creates key-person risk and raises the bar for disciplined succession, acquisition, repurchase, and product allocation decisions.
Life sciences companies need more digital compliance, faster clinical workflows, better commercial evidence, and AI-assisted productivity. The trend is favorable, but drug pricing, trial funding, and regulatory uncertainty can slow customer spending.
The current price implies that Veeva can convert its fiscal 2027 guidance, $7.31 billion cash and short-term investment base, and AI roadmap into durable per-share growth. The margin of safety is moderate, not high, because the valuation still assumes execution.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $189.02 intraday on July 8, 2026 | StockAnalysis VEEV statistics | July 8, 2026 |
| Market cap and shares outstanding | $30.71B market cap, 162.44M shares outstanding | StockAnalysis VEEV statistics | July 8, 2026 |
| Q1 fiscal 2027 revenue | $882.9M total revenue, up 16% year over year | Veeva Q1 fiscal 2027 results | July 8, 2026 |
| Q1 fiscal 2027 net income | $260.9M net income and $1.57 diluted EPS | Veeva Q1 fiscal 2027 results | July 8, 2026 |
| FY2026 revenue | $3.195B total revenue, cross-checked with Macrotrends | Veeva FY2026 results | July 8, 2026 |
| FY2026 net income | $908.9M net income, cross-checked with Macrotrends | Veeva FY2026 results | July 8, 2026 |
| Cash and short-term investments | $7.31B as of April 30, 2026 | Veeva Q1 fiscal 2027 balance sheet | July 8, 2026 |
| Fiscal 2027 guidance | $3.635B to $3.645B revenue and about $9.05 non-GAAP diluted EPS | Veeva Q1 fiscal 2027 outlook | July 8, 2026 |
| Technical levels | RSI 50.013, MACD 1.97, 50-day SMA $184.17, 200-day SMA $170.75 | Investing.com VEEV technical analysis | July 8, 2026 |
| Alternative technical cross-check | 20-day average $169.75, 50-day $167.35, 200-day $212.10 | Barchart VEEV technical analysis | July 8, 2026 |
This VEEV AI stock analysis page is an informational research tool only. It is not investment advice, financial planning, a recommendation to buy or sell securities, or a promise of future performance. Forecast ranges are scenarios based on available public data and may be wrong.
